Dr. Lowell Anthony, MD, FACP
Claim this profileUniversity of Kentucky/Markey Cancer Center
Area of expertise
Neuroendocrine Tumors
Lowell Anthony, MD, FACP has run 4 trials for Neuroendocrine Tumors. Some of their research focus areas include:
Carcinoid Tumor
Lowell Anthony, MD, FACP has run 3 trials for Carcinoid Tumor. Some of their research focus areas include:
Affiliated Hospitals
University Of Kentucky/Markey Cancer Center
Ohio State University Comprehensive Cancer Center LAO
Clinical Trials Lowell Anthony, MD, FACP is currently running
Targeted Alpha-Particle Therapy
for Neuroendocrine Tumors
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Recruiting
1 award
Phase 1 & 2
13 criteria
Radioactive Drug vs Everolimus
for Neuroendocrine Cancer
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to a peptide (small protein) that targets tumor cells. When this radioactive peptide is injected into the body, it binds to a specific receptor found on some tumor cells. The radioactive peptide builds up in these cells and helps kill the tumor cells without harming normal cells. In this trial 177Lu-DOTATATE is used for PRRT. 177Lu-DOTATATE PRRT may increase the length of time until worsening of the GEPNET compared to the usual approach. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping tumor cells from reproducing and by decreasing blood supply to the tumor cells. Sunitinib and cabozantinib, block certain proteins, which may help keep tumor cells from growing. They may also prevent the growth of new blood vessels that tumors need to grow. Sunitinib malate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Retreating with 177Lu-DOTATATE may work better than everolimus, sunitinib or cabozantinib in shrinking or stabilizing tumors in patients with metastatic and unresectable GEPNET who were previously treated with 177Lu-DOTATATE.
Recruiting
1 award
Phase 2
More about Lowell Anthony, MD, FACP
Clinical Trial Related
2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Lowell Anthony, MD, FACP has experience with
- Lutetium Lu 177 Dotatate
- Triapine
- Cabozantinib S-malate
- Peposertib
- Everolimus
- [212Pb]VMT-α-NET
Breakdown of trials Lowell Anthony, MD, FACP has run
Neuroendocrine Tumors
Carcinoid Tumor
Lung carcinoid
Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lowell Anthony, MD, FACP specialize in?
Lowell Anthony, MD, FACP focuses on Neuroendocrine Tumors and Carcinoid Tumor. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Lowell Anthony, MD, FACP currently recruiting for clinical trials?
Yes, Lowell Anthony, MD, FACP is currently recruiting for 2 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Lowell Anthony, MD, FACP has studied deeply?
Yes, Lowell Anthony, MD, FACP has studied treatments such as Lutetium Lu 177 Dotatate, Triapine, Cabozantinib S-malate.
What is the best way to schedule an appointment with Lowell Anthony, MD, FACP?
Apply for one of the trials that Lowell Anthony, MD, FACP is conducting.
What is the office address of Lowell Anthony, MD, FACP?
The office of Lowell Anthony, MD, FACP is located at: University of Kentucky/Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky/Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.